News | February 18, 2023
Lupin receives EIR from USFDA for injectable facility in Nagpur
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
The approval for Glycopyrrolate clears the path for more internally manufactured injectable products
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
A pharma industry veteran with over three decades of experience in domestic as well as international markets
_256_384.jpg)
Through this important initiative, Lupin Life encourages children from Mumbai, Thane, and Navi Mumbai to participate in the Aptivate Champion Run
The only robotic-arm assisted surgical device to conduct joint replacement with accuracy and better clinical outcomes
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
Biocon Foundation has pioneered a mHealth-technology-based (mobile health) oral cancer screening program in India
Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure
Subscribe To Our Newsletter & Stay Updated
